...2012 (see BioCentury, Dec. 3, 2012). Leo gained the product through its 2009 acquisition of Peplin...

...year (see BioCentury, Dec. 3, 2012). Leo gained the product through its 2009 acquisition of Peplin...

...year (see BioCentury, Dec. 3, 2012). Leo gained the product through its 2009 acquisition of Peplin...

...Universitaetsmedizin Berlin (see BioCentury, Oct. 8). Leo gained the product through its 2009 acquisition of Peplin...

...Fund I include dermatology company Peplin Inc. and autoimmune and cancer play Arana Therapeutics Ltd. Peplin...

...in January (see BioCentury, Jan. 30). Leo gained the product through its 2009 acquisition of Peplin...

...is an ingenol 3-angeloyl topical formulation. Leo gained the product through its 2009 acquisition of Peplin...

...Inc. CEO Thomas Wiggans and CMO Eugene Bauer were both involved with Connetics Corp. and Peplin...
...five dermatology products to market (see BioCentury, Oct. 30, 2006) . The pair reconnected at Peplin...

...or acquire. Dermira's CEO is Tom Wiggans, who is the former chairman and CEO of Peplin...
...Inc. and former CEO of Connetics Corp. The CMO is Eugene Bauer, formerly CMO of Peplin...

...PEP005 has been submitted for FDA review. Leo gained PEP005 through its 2009 acquisition of Peplin...